Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Estrella Immunopharma, Inc.

Get SEC filing alerts via email and in your feed for Estrella Immunopharma, Inc.

ESLA ESLAW

Estrella Immunopharma, Inc.

About Estrella Immunopharma, Inc.

Estrella Immunopharma is a biopharmaceutical company focused on developing T-cell therapies for cancer and autoimmune diseases. Its core platform, ARTEMIS, enables targeted, regulated immune responses to treat hematologic malignancies and solid tumors, with an emphasis on safety and efficacy. The company leverages innovative T-cell engineering to address limitations of existing immunotherapies, aiming to provide safer, more effective treatments for patients worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Estrella Immunopharma, Inc.

1
1
Estrella Immunopharma, Inc. Estrella Immunopharma Reports $2.3 Million Net Loss and Increased Operating Expenses for Q1 2026

Via official filing (AI summary) | 17 days ago | 0 comments

2
1
Estrella Immunopharma, Inc. Estrella Immunopharma Reports $13.1 Million Net Loss and Increased R&D Expenses for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Estrella Immunopharma, Inc. Estrella Immunopharma Reports Increased Net Losses and Rising R&D Expenses for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Estrella Immunopharma, Inc. Estrella Immunopharma Reports Increased Net Loss and Decreased Total Assets for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Estrella Immunopharma, Inc. Estrella Immunopharma Reports Increased Losses and Financial Challenges in Latest 10-Q Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Estrella Immunopharma, Inc. Estrella Immunopharma Reports Significant Financial Decline, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments